TG02

Ligand id: 9095

Name: TG02

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 0
Topological polar surface area 50.28
Molecular weight 372.2
XLogP 4.29
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

References
1. Goh KC, Novotny-Diermayr V, Hart S, Ong LC, Loh YK, Cheong A, Tan YC, Hu C, Jayaraman R, William AD et al.. (2012)
TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties.
Leukemia, 26 (2): 236-43. [PMID:21860433]
2. Pallis M, Abdul-Aziz A, Burrows F, Seedhouse C, Grundy M, Russell N. (2012)
The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells.
Br. J. Haematol., 159 (2): 191-203. [PMID:22934750]
3. Pallis M, Burrows F, Whittall A, Boddy N, Seedhouse C, Russell N. (2013)
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
BMC Pharmacol Toxicol, 14: 32. [PMID:23767415]
4. Poulsen A, William A, Blanchard S, Nagaraj H, Williams M, Wang H, Lee A, Sun E, Teo EL, Tan E et al.. (2013)
Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).
J Mol Model, 19 (1): 119-30. [PMID:22820730]
5. William AD, Lee AC, Goh KC, Blanchard S, Poulsen A, Teo EL, Nagaraj H, Lee CP, Wang H, Williams M et al.. (2012)
Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer.
J. Med. Chem., 55 (1): 169-96. [PMID:22148278]